The diagnostic criteria for hypertension have been lowered, and the drug market may usher in an outbreak

Hypertension is a chronic non-communicable disease with a large number of patients in China, the most important risk factor for cardiovascular and cerebrovascular diseases, and the main complication
of stroke, myocardial infarction, heart failure and chronic kidney disease.
In recent years, with the continuous improvement of health awareness, the public's attention to the problem of hypertension has also increased
.
Recently, the National Center for Cardiovascular Diseases, the Chinese Medical Doctor Association, the Hypertension Professional Committee of the Chinese Medical Doctor Association, and the Cardiovascular Disease Branch of the Chinese Medical Association jointly released a new version of the "Chinese Clinical Practice Guidelines for Hypertension"
.
The guidelines were developed by experts in multiple fields, mainly cardiovascular and hypertension, and formed 44 key clinical questions and 102 recommendations for hypertension
.
Among them, it is recommended to lower the diagnostic threshold of hypertension in adults in China to systolic blood pressure greater than or equal to 130 mm Hg and/or diastolic blood pressure greater than or equal to 80 mm Hg
.
The results of the study show that among young people under 40 years old in China, the risk of stroke in people with blood pressure values of 130 to 139/80 to 89mmHg is significantly increased
, especially the risk of cerebral hemorrhage.
The recommended diagnostic standard for hypertension was changed to 130/80mmHg, which has clear necessity and feasibility for the prevention of cardiovascular and cerebrovascular diseases in China, especially stroke.
It can allow more people to pay attention to blood pressure from a higher stage, lower blood pressure, and significantly reduce the occurrence
of cardiovascular and cerebrovascular complications.
It is worth noting that in contrast to the lowering of the threshold for hypertension, the number of hypertensive patients will also increase
significantly.
In this regard, the industry believes that the antihypertensive drug market will continue to expand, and related manufacturers of drugs for the treatment of hypertension will usher in huge market opportunities
.
It is understood that under the diagnostic standard of 140/90mmHg, the sales scale of China's antihypertensive drug market has shown a steady growth trend, and the market size of China's antihypertensive drugs in 2020 is about 95.
6 billion yuan, an increase of 8% year-on-year, and the future market scale continues to expand, and it is expected that the market size of antihypertensive drugs in China will reach 103.
5 billion yuan
in 2022.
There are many varieties of antihypertensive drugs, and the current antihypertensive drugs mainly include calcium antagonists, renin-angiotensin-aldosterone system inhibitors, adrenergic receptor blockers, compound antihypertensive drugs, diuretics, etc
.
The Guidelines also give certain medication recommendations, including recommending initial treatment as a combination of drugs, and giving preference to single-tablet combination preparations (ACEI/ARB+CCB or ACEI/ARB+diuretics).

In fact, compound antihypertensive drugs have been favored by the market with their advantages of good compliance and convenience, and the market has grown significantly
in recent years.
According to the data, the market size of compound antihypertensive drugs in 2018 was about 10.
36 billion yuan, a year-on-year increase of 4.
1%, with a rapid growth rate, and it is expected that the market size of compound antihypertensive drugs will reach 21.
09 billion yuan
in 2030.
In general, the huge population of hypertension is undoubtedly providing a broad space
for the development of China's antihypertensive drug market.
The hypertension drug recommendation is expected to further drive the continuous release of market demand for antihypertensive drugs, and the market scale will continue to expand
in the future.
In this context, pharmaceutical companies are actively carrying out innovative research and development in the field of hypertension drugs, which is expected to be promising
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.